


Claims

1. A composition comprising a compound according to formula (I):




wherein:

- 5 R^1 is chloro, R^2 is ethyl or hydrogen, and R^3 is hydrogen,
or a pharmaceutically acceptable salt thereof, for use in the treatment of an eye
disease or eye disorder selected from the group consisting of corneal
neovascularisation, neovascularisation of the iris, neovascularisation of the
ciliary body, corneal pannus, choroidal neovascularisation, retinal
10 neovascularisation, wet age-related macular degeneration, proliferative diabetic
retinopathy, retinopathy of prematurity, and ischemic retinopathy.

2. The composition for use according to claim 1, wherein the compound is
laquinimod, or a pharmaceutically acceptable salt thereof.

15

3. The composition for use according to claim 1, wherein the compound is a
compound of formula (IV):



20

or a pharmaceutically acceptable salt thereof.

4. The composition for use according to any one of the preceding claims, wherein
the eye disease or eye disorder is selected from the group consisting of corneal
neovascularisation, neovascularisation of the iris, neovascularisation of the
ciliary body, and corneal pannus.

25

5. The composition for use according to claim 4, wherein the eye disease or eye
disorder is corneal neovascularisation.

- 5 6. The composition for use according to any one of claims 1 to 3, wherein the eye disease or eye disorder is selected from the group consisting of proliferative diabetic retinopathy, retinopathy of prematurity, and ischemic retinopathy.
7. The composition for use according to claim 6, wherein the eye disease or eye disorder is proliferative diabetic retinopathy.
- 10 8. The composition for use according to claim 6, wherein the eye disease or eye disorder is retinopathy of prematurity.
9. The composition for use according to claim 6, wherein the eye disease or eye disorder is ischemic retinopathy.
- 15 10. The composition for use according to any one of claims 1 to 3, wherein the eye disease or eye disorder is selected from the group consisting of choroidal neovascularisation, retinal neovascularisation, and wet age-related macular degeneration.
- 20 11. The composition for use according to claim 10, wherein the eye disease or eye disorder is choroidal neovascularisation.
12. The composition for use according to claim 10, wherein the eye disease or eye disorder is retinal neovascularisation.
- 25 13. The composition for use according to claim 10, wherein the eye disease or eye disorder is wet age-related macular degeneration.
- 30 14. The composition for use according to any one of the preceding claims, wherein the composition comprises or is administered in combination with an angiogenesis inhibitor, such as aflibercept.
- 35 15. The composition for use according to any one of the preceding claims, wherein the composition comprises or is administered in combination with a VEGF inhibitor.

16. The composition for use according to claim 15, wherein the VEGF inhibitor is selected from the group consisting of aflibercept, ranibizumab, bevacizumab, brolucizumab, abicipar pegol, conbercept, and faricimab.

5

17. The composition for use according to any one of the preceding claims, wherein the composition comprises or is administered in combination with at least one pharmaceutically acceptable excipient.


10

18. The composition for use according to any one of the preceding claims, wherein the route of administration is topical, oral, intravitreal, subconjunctival, retrobulbar, intracameral, or systemic.

15

19. A method of treating an eye disease or eye disorder selected from the group consisting of corneal neovascularisation, neovascularisation of the iris, neovascularisation of the ciliary body, corneal pannus, choroidal neovascularisation, retinal neovascularisation, wet age-related macular degeneration, proliferative diabetic retinopathy, retinopathy of prematurity, and ischemic retinopathy, said method comprising administering a composition comprising a therapeutically effective amount of a compound according to formula (I):

20




wherein:

R¹ is chloro, R² is ethyl or hydrogen, and R³ is hydrogen,

25

or a pharmaceutically acceptable salt thereof, to a subject in need thereof.

20. Use of a compound according to formula (I):



formula (I),

wherein:

R¹ is chloro, R² is ethyl or hydrogen, and R³ is hydrogen,

or a pharmaceutically acceptable salt thereof for the manufacture of a

5 medicament for the treatment of an eye disease or eye disorder selected from the group consisting of corneal neovascularisation, neovascularisation of the iris, neovascularisation of the ciliary body, corneal pannus, choroidal neovascularisation, retinal neovascularisation, wet age-related macular degeneration, proliferative diabetic retinopathy, retinopathy of prematurity, and

10 ischemic retinopathy.

15